Date: Tuesday, June 4, 2019
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: Previous studies have identified treatment disparities in the treatment of hepatocellular carcinoma (HCC) based on insurance status and provider. Recent studies have shown more Americans have healthcare insurance; therefore we aim to determine if treatment disparities based on insurance provider continue to exist.
*Methods: A retrospective database analysis using the Nationwide Inpatient Sample was performed between 2010 and 2013 including adult patients with a primary diagnosis of HCC determined by ICD-9 codes. Multivariable logistic regressions were performed to analyze difference in treatment, mortality, features of decompensation, and metastatic disease based on the patient’s primary payer.
*Results: This study included 62,368 patients. Medicare represented 44% of the total patients followed by private insurance (27%), Medicaid (19%), and other payers (10%). Patients with Medicare, Medicaid and other payers were less likely to undergo liver transplantation (OR 0.63, 95% CI 0.47-0.84), (OR 0.23, 95% CI 0.15-0.33), (OR 0.26, 95% CI 0.15-0.45) and surgical resection (OR 0.23, 95% CI 0.63-0.87), (OR 0.40, 95% CI 0.32-0.51), (OR 0.42, 95% CI 0.32-0.54) than patients with private insurance. Medicaid patients were less likely to undergo ablation then patients with private insurance (OR 0.52, 95% CI 0.40-0.68). Patients with other forms of insurance were less likely to undergo transarterial chemoembolization (TACE) compared to patients with private insurance (OR 0.64, 95% CI 0.43-0.96).
*Conclusions: Insurance status impacts treatment for HCC. Patients with private insurance are more likely to undergo curative therapies of liver transplantation and surgical resection compared to patients with government funded insurance.
To cite this abstract in AMA style:Sobotka L, Hinton A, Conteh L. Insurance Status Impacts Treatment for Hepatocellular Carcinoma [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/insurance-status-impacts-treatment-for-hepatocellular-carcinoma/. Accessed June 3, 2020.
« Back to 2019 American Transplant Congress